Radiation Oncology Journal

  • 제34권4호
  • /
  • Pages.297-304
  • /
  • 2016
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Postoperative radiotherapy appeared to improve the disease free survival rate of patients with extrahepatic bile duct cancer at high risk of loco-regional recurrence

  • Kim, Mi Young (Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Jin Hee (Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Yonghoon (Department of Surgery, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Byun, Sang Jun (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2016.07.19
  • 심사 : 2016.10.04
  • 발행 : 2016.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To investigate the outcomes of postoperative radiotherapy (RT), in patients with extrahepatic bile duct (EHBD) cancer by comparing the survival rate between patients undergoing surgery alone or surgery plus postoperative RT, and to identify the prognostic factors affecting survival. Materials and Methods: Between 2000 and 2013, 52 patients with EHBD cancer underwent surgical resection. Of these, 33 patients did not receive postoperative RT (group I), and 19 patients did (group II). R1 resection was significantly more frequent in group II. The median radiation dose was 5,040 cGy. Results: The 3-year overall survival (OS) rate for group I and group II was 38% and 56%, respectively (p = 0.274). The 3-year disease free survival (DFS) rate for group I and group II was 20% and 31%, respectively (p = 0.049), and the 3-year loco-regional recurrence free survival (LRFS) rates were 19% and 58%, respectively (p = 0.002). Multivariate analyses showed that postoperative RT and lymphovascular invasion were independent prognostic factors for DFS and LRFS. Overall, 42 patients (80%) experienced treatment failure. Distant metastasis was the predominant pattern of failure in group II. Conclusion: Postoperative RT after surgical resection appeared to improve the loco-regional control and DFS rate. More effort is needed to reduce distant metastasis, the major pattern of failure, in patients who receive postoperative RT.

키워드

참고문헌

  1. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015;47:127-41. https://doi.org/10.4143/crt.2015.060
  2. Kopelson G, Galdabini J, Warshaw AL, Gunderson LL. Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1981;7:413-7. https://doi.org/10.1016/0360-3016(81)90118-8
  3. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-700. https://doi.org/10.1002/cncr.11699
  4. Koo TR, Eom KY, Kim IA, et al. Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy. Radiat Oncol J 2014;32:63-9. https://doi.org/10.3857/roj.2014.32.2.63
  5. Gazzaniga GM, Filauro M, Bagarolo C, Mori L. Surgery for hilar cholangiocarcinoma: an Italian experience. J Hepatobiliary Pancreat Surg 2000;7:122-7. https://doi.org/10.1007/s005340050165
  6. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73. https://doi.org/10.1097/00000658-199610000-00005
  7. Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010;78:194-8. https://doi.org/10.1016/j.ijrobp.2009.07.003
  8. Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 2005;241:77-84.
  9. Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008;15:3147-56. https://doi.org/10.1245/s10434-008-9998-7
  10. Kim K, Chie EK, Jang JY, et al. Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol 2012;35:136-40. https://doi.org/10.1097/COC.0b013e318209aa29
  11. Lillemoe KD, Cameron JL. Surgery for hilar cholangiocarcinoma: the Johns Hopkins approach. J Hepatobiliary Pancreat Surg 2000;7:115-21. https://doi.org/10.1007/s005340050164
  12. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-17. https://doi.org/10.1097/00000658-200110000-00010
  13. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery 2002;132:555-63. https://doi.org/10.1067/msy.2002.127555
  14. Park JH, Choi EK, Ahn SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696-704. https://doi.org/10.1016/j.ijrobp.2009.12.031
  15. Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002;54:414-9. https://doi.org/10.1016/S0360-3016(02)02952-8
  16. Stein DE, Heron DE, Rosato EL, Anne PR, Topham AK. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am J Clin Oncol 2005;28:21-3. https://doi.org/10.1097/01.coc.0000139017.90599.f5
  17. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934-40. https://doi.org/10.1200/JCO.2011.40.5381
  18. Matsuda T, Fujita H, Harada N, et al. Impact of adjuvant radiation therapy for microscopic residual tumor after resection of extrahepatic bile duct cancer. Am J Clin Oncol 2013;36:461-5. https://doi.org/10.1097/COC.0b013e31825494ab
  19. Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009;73:148-53. https://doi.org/10.1016/j.ijrobp.2008.07.008
  20. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 2015;33:2617-22. https://doi.org/10.1200/JCO.2014.60.2219
  21. National Comprehensive Cancer Network. Hepatobiliary cancer (version 2. 2016) [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2016 [cited 2016 Oct 24]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.

피인용 문헌

  1. Role of adjuvant radiotherapy for localized extrahepatic bile duct cancer vol.90, pp.1071, 2016, https://doi.org/10.1259/bjr.20160807
  2. Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution vol.8, pp.44, 2016, https://doi.org/10.18632/oncotarget.17368
  3. Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery vol.90, pp.1080, 2017, https://doi.org/10.1259/bjr.20170308
  4. Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy vol.35, pp.4, 2017, https://doi.org/10.3857/roj.2017.00388
  5. Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma vol.20, pp.8, 2016, https://doi.org/10.1007/s12094-017-1815-y
  6. The impact of perioperative CA19‐9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma vol.117, pp.3, 2016, https://doi.org/10.1002/jso.24856
  7. High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients vol.44, pp.5, 2016, https://doi.org/10.1016/j.ejso.2018.01.012
  8. Risk factors associated with locoregional failure and estimation of survival after curative resection for patients with distal bile duct cancer vol.9, pp.None, 2016, https://doi.org/10.1038/s41598-019-41622-2
  9. Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives vol.7, pp.11, 2019, https://doi.org/10.12998/wjcc.v7.i11.1242
  10. Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer vol.37, pp.4, 2019, https://doi.org/10.3857/roj.2019.00430
  11. Is it necessary to receive radiation for pT3‐4N0 oral cancer without other adverse risk features? vol.26, pp.6, 2016, https://doi.org/10.1111/odi.13336